Assess whether labeling language overclaims the evidence (d25fec)

Situation

The Pharmacovigilance desk packet is CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences file. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• CMC comparability package for a site change reads as Proceed under protocol once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• CMC comparability package for a site change is closer to Pause the pathway after an FAERS cluster in a demographic the trials under-enrolled; Proceed under protocol would over-claim this Pharmacovigilance extract.
• Escalate safety review is still live in CMC comparability package for a site change for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.
• CMC comparability package for a site change is missing the fact 505(b)(2) development lead needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on labeling language overclaims the.
• Check whether CMC comparability package for a site change supports the labeled claim 505(b)(2) development lead would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move labeling language overclaims the for 505(b)(2) development lead.

Recommendation